CareDx ‘respectfully disagrees’ with Supreme Court decision in patent case

CareDx (CDNA) acknowledged the Supreme Court’s decision not to review the Federal Circuit’s decision on the patent eligibility of three Stanford-licensed patents. CareDx notes the decision does not impact the company’s ability to continue providing AlloSure donor-derived cell-free DNA. While CareDx respectfully disagrees with the Supreme Court’s decision, the case law applies equally to other transplant diagnostics patents, including Natera’s (NTRA), and CareDx has filed a motion to invalidate Natera’s patents on these same grounds.